deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02959437

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)

Sponsor: Incyte Corporation

Updated 17 times since 2017 Last updated: Oct 20, 2025 Started: Feb 27, 2017 Primary completion: Feb 15, 2019 Completion: Mar 2, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated by Sponsor

This PHASE1/PHASE2 trial investigates Advanced Malignancies and Metastatic Cancer and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Feb 2018 · 10 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Apr 2019 · 9 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

17 versions recorded
  1. Nov 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Nov 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  4. Jun 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: CompletedTerminated

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE1_PHASE2

Show 12 earlier versions
  1. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not RecruitingCompleted

  2. Nov 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jul 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

  6. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet RecruitingRecruiting

  11. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .